Acute Coronary Syndromes Clinical Trial
Official title:
Effects of the Self-management on Anxiety, Depression, Quality of Life and Self-management of Patients With Acute Coronary Syndromes: a Randomized Controlled Trial.
Verified date | April 2024 |
Source | Taipei Veterans General Hospital, Taiwan |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Purpose : The purpose of this study is to investigate the tracking effect of selfmanagement programs on anxiety, depression, and quality of life in patients with Acute Coronary Syndromes (ACS).
Status | Enrolling by invitation |
Enrollment | 104 |
Est. completion date | August 26, 2024 |
Est. primary completion date | August 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 100 Years |
Eligibility | Inclusion Criteria: - Over 20 years old - The first diagnosis of acute coronary syndrome by a clinician, - Clear consciousness, able to converse in Chinese and Taiwanese languages. - Willingness to participate in this research Exclusion Criteria: - Those who are unable to take care of themselves - Poor vision and inability to read - Hard of hearing and deafness - Inability to communicate |
Country | Name | City | State |
---|---|---|---|
Taiwan | Taipei Veterans General Hospital | Taipei county, |
Lead Sponsor | Collaborator |
---|---|
Taipei Veterans General Hospital, Taiwan |
Taiwan,
Bandura, A. (1977). Self-efficacy: toward a unifying theory of behavioral change. Psychological Review, 84(2), 191-215. https:// doi.org/10.1037//0033-295x.84.2.191 Gach, O., El, H. Z., & Lancellotti, P.(2018). [Acute coronary syndrome]. Revue Médicale de
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Hospital Anxiety and Depression Scale, HADS | The Likert four-point scale (0-3 points) was used, and the two items were scored separately, and the total score was between 0-21 points. The higher the score, the higher the degree of anxiety or depression. A score below 7 means no anxiety or depression, a score between 8 and 10 means the patient is suspected of anxiety or depression, and a score greater than or equal to 11 means that the patient has anxiety or depression.
It is a measure to assess change at three-time points. change from Baseline Anxiety and Depression at 1 and 3 months. |
First time(baseline) is in the first day in the ward.The second time is one month after discharge.The third time is three months after discharge. | |
Primary | The MOS 36-Item Short-Form Health Survey,SF36 | Scores range from 0 to 100, with higher scores indicating better self-assessed health. Each item of the questionnaire is calculated separately according to the designed initial scores. Then the scores of the items related to each scale are added up and then subtracted from each scale to obtain the lowest score. Divide by the distance between the possible scores of each scale, and multiply by 100 to get the score.
It is a measure to assess change at three-time points. change from Baseline quality of life at 1 and 3 months. |
First time(baseline) is in the first day in the ward.The second time is one month after discharge.The third time is three months after discharge | |
Primary | The Partner In Health scale, PIH | Items in the scale are graded on a nine-point scale, with 0 representing the worst and 8 representing the best. This is a closed and continuous variable. The scale scores range from 0 to 96, with higher scores indicating better selfmanagement.
It is a measure to assess change at three-time points. Change from self-management Baseline at 1 and 3 months. |
First time(baseline) is in the first day in the ward.The second time is one month after discharge.The third time is three months after discharge |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02552407 -
Thrombectomy in ST Elevation Myocardial Infarction, an Individual Patient Meta-analysis
|
N/A | |
Completed |
NCT01398228 -
Clinical Pathways for the Management of Acute Coronary Syndromes - Phase 3,CPACS-3
|
N/A | |
Completed |
NCT01135667 -
Prasugrel Versus Double Dose Clopidogrel to Treat Clopidogrel Low-responsiveness After PCI
|
Phase 4 | |
Recruiting |
NCT02592720 -
Cocktail Injection Improves Outcomes of FFR Guided PCI
|
Phase 4 | |
Completed |
NCT01641510 -
PRAsugrel or clopIdogrel In Acute Coronary SyndromE With CYP2C19 GENEtic Variants
|
Phase 3 | |
Completed |
NCT01743274 -
Does Optical Coherence Tomography Optimise Results of Stenting
|
N/A | |
Active, not recruiting |
NCT01433627 -
Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX
|
Phase 3 | |
Completed |
NCT01452282 -
Ankle-Brachial Index Estimating Cardiac Complications After Surgery
|
N/A | |
Recruiting |
NCT01418794 -
Efficacy and Safety of the YUKON Drug Eluting Stent in Diffuse Coronary Artery Disease
|
Phase 4 | |
Recruiting |
NCT01000701 -
Inflammation and Acute Coronary Syndromes
|
N/A | |
Terminated |
NCT01107899 -
Study to Learn When Platelets Return to Normal After One Loading Dose of Anti-platelet Drugs in Patients With Symptoms of Acute Coronary Syndromes
|
Phase 1 | |
Completed |
NCT00494247 -
Endothelial Progenitor Cells-capture Stents in Acute Coronary Syndromes
|
Phase 4 | |
Terminated |
NCT00615719 -
Computed Tomographic Coronary Angiography for Acute Chest Pain Evaluation
|
N/A | |
Active, not recruiting |
NCT06089343 -
High-risk Features of Coronary Lesions in CTA and OCT
|
||
Not yet recruiting |
NCT04023630 -
DUAL Antithrombotic Therapy in Patients With AF and ACS
|
Phase 4 | |
Recruiting |
NCT02601404 -
REal World Advanced Experience of BioResorbable ScaffolD by SMart Angioplasty Research Team (SMART REWARD)
|
N/A | |
Completed |
NCT02195193 -
Integrating Depression Care in Acute Coronary Syndromes Care in China
|
N/A | |
Completed |
NCT02141750 -
THIRD NATIONAL REGISTRY OF ACUTE CORONARY SYNDROMES
|
N/A | |
Not yet recruiting |
NCT01735227 -
Omeprazole and Pantoprazole Antiplatelet Effect of Clopidogrel Clinical Trials(OPEN)
|
Phase 4 | |
Completed |
NCT00097591 -
A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention
|
Phase 3 |